RecruitingNot ApplicableNCT07485517

Deep Versus Moderate Neuromuscular Blocking

The Effect of Deep Versus Moderate Neuromuscular Blocking on Patients Undergoing Open Hysterectomy

Sponsor

Menoufia University

Enrollment

88 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

Change in Serum Levels of the Estimated Inflammatory Cytokines Total Dose of IO Fentanyl PO Morphine Surgeons' Rating Pain Scores

Summary

This study aimed for Determination of the impacts of deep neuromuscular blockade (DNMB) on surgical outcomes, consumption of perioperative opioid analgesia, and serum levels of inflammatory cytokines in comparison to moderate NMB (MNMB).

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Deep neuromuscular block and a drug called Moderate Neuromuscular Blockade for people with change in serum levels of the estimated inflammatory cytokines, po morphine, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGModerate Neuromuscular Blockade

A TOF-Watch® SX-acceleromyograph will be applied to the adductor pollicis muscle and calibrated to monitor response and degree of NMB. Anesthesia will be induced with IV propofol (1.5-2.5 mg/kg) and rocuronium bromide 0.6 mg/Kg, and the trachea will be intubated at train-of-four (TOF) 0. Anesthesia will be maintained with 50% air in oxygen and an end-tidal concentration of 2-3% sevoflurane. In the DNMB group, rocuronium infusion was used to provide 0.48-0.72 mg/kg/h to maintain PTC 0-1.

DRUGDeep neuromuscular block

For patients in the MNMB group, rocuronium will be given as 0.2 mg/kg to maintain a post-tetanic count (PTC) of \>1, and TOF in the range of 0-2.

Locations(1)

Faculty of Medicine Menoufia University

Menoufia, Eg.mn, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07485517